Skip to content

The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects

A Randomized, Double-blind, Placebo-controlled, Two-way Crossover Trial to Compare Moxifloxacin Induced QT Interval Prolongation in Japanese and Korean Healthy Subjects

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01876316
Enrollment
40
Registered
2013-06-12
Start date
2011-11-30
Completion date
2013-01-31
Last updated
2013-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Moxifloxacin, QT interval prolongation, Korean, Japanese

Brief summary

The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects

Detailed description

The purpose of this study is to explore the ethnic and gender difference in the Moxifloxacin induced QT interval prolongation between Japanese and Korean subjects.

Interventions

DRUGMoxifloxacin

single oral administration of 400mg of moxifloxacin

DRUGPlacebo

single oral administration of 400mg of placebo

Sponsors

Inje University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

\- 1) Subjects in Japan and Korea deemed healthy as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, or clinical laboratory determinations. 2\) Body Mass Index (BMI) of 17.6 to 26.4 kg/m2, BMI = weight (kg)/ \[height (m)\]2.

Exclusion criteria

* 1\) Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population. 2\) Any of the following on 12-lead ECG prior to study drug administration, confirmed by repeat. * Heart rate ≤ 45 bpmmsec or Heart rate ≥ 100 bpmmsec * PR ≥ 210 msec * QRS ≥ 120 msec * QT ≥ 500 msec * QTcF: male ≥ 450 msec, female ≥470msec * Iincomplete right bundle branch block * Marked Sinus Arrhythmia * Wondering pacemaker * Atrial rhythm

Design outcomes

Primary

MeasureTime frameDescription
double delta QTcFup to 24 hours12 point of ECG measurements according to the interventions

Secondary

MeasureTime frame
double delta QTcI, double delta QTcSSup to 24 hours

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026